IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: IDYA) | Delayed: 34.71 -1.41 (3.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.12 | 52 Week High | $ | |||
| Open | $36.35 | 52 Week Low | $ | |||
| Day High | $36.35 | P/E | N/A | |||
| Day Low | $34.54 | EPS | $ | |||
| Volume | 1,128,966 | |||||
